KZKai Zhu

Kai Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kai Zhu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Chi Zhang

    College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China

    1 shared publication
  • Helena Tomás

    CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal

    1 shared publication
  • Jieying Yuan

    College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China

    1 shared publication
  • Lin Xing

    College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China

    1 shared publication
  • Qidong Tu

    Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China

    1 shared publication
  • Ruihua Guo

    College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China; Department of Marine Biopharmacology, College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China; Marine Biomedical Science and Technology Innovation Platform of Lin-gang Special Area, Shanghai 201306, China

    1 shared publication

Latest Publications

  • Open Access

    Progress of ERK Pathway-Modulated Natural Products for Anti-Non-Small-Cell Lung Cancer Activity

    by Lin Xing, Chi Zhang, Jieying Yuan, Kai Zhu, Helena Tomás, Ruilong Sheng, Xiuwei H. Yang, Qidong Tu, Ruihua Guo

    In recent decades, there has been a significant increase in new lung cancer cases and deaths globally, especially in China, which hindered the extension of human life expectancy and severely threatened public health. Natural products are important and sustainable sources of new anticancer drug molecules, offering new bioactive molecules with various structures and biofunctions for new anticancer drug development, which accounted for 40% of all anticancer drugs. Natural-based compounds could inhibit cancer cell proliferation and migration through a variety of anticancer mechanisms by the modulation/regulation of multiple biotargets and cell signaling pathways. In this review, we summarized the anticancer activities of flavonoids, terpenoids, glycosides, alcohols, coumarins, saccharides, and other natural compounds that could modulate the ERK-related signaling pathway in non-small-cell lung cancer (NSCLC) cells. We further elucidated the mechanistic pathways of natural compound combinations and computationally predicted their molecular docking affinities with ERK1/ERK2 protein targets, as well as providing an outlook on current studies, with the expectation that natural compounds will play more significant roles in future antitumor chemotherapy regimens.